KURA News and Press, Kura Oncology Inc. From 10/30/19

SAN DIEGO, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report third quarter 2019 financial results after the close...

– 56% confirmed ORR in 18 efficacy-evaluable HNSCC patients with HRAS mutant variant allele frequency ≥ 20% – – Median progression-free survival of 6.1 months vs. 2.8 months on last prior therapy – – 8 efficacy-evaluable patients enrolled since...

– Data from Phase 2 clinical trial of tipifarnib in HRAS mutant HNSCC selected for short-talk during Spotlight on Proffered Papers session on Tuesday, October 29 th – – Previously announced poster presentation rescheduled to take place following oral presentation &#x...

Noteworthy events during the week of October 20 - 26 for healthcare investors. More news on: Foamix Pharmaceuticals Ltd., Axovant Gene Therapies Ltd., GlaxoSmithKline plc, Healthcare stocks news, , Read more ...

SAN DIEGO, Oct. 16, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that an abstract related to the Company’s Phase 2 clinical trial ...

SAN DIEGO, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced the appointment of veteran commercial executive Diane Parks to its board...

– KO-539 is a first-in-class small molecule inhibitor of the menin-MLL interaction – – First-in-human trial to determine MTD, expand to genetic subgroups such as NPM1 – SAN DIEGO, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clini...

Results from an investigator-sponsored Phase 2 clinical trial evaluating Kura Oncology's ( KURA +1.9% ) tipifarnib in patients with relapsed/refractory HRAS mutation-positive urothelial carcinoma showed a positive effect on progression-free survival (PFS) at month 6. More news on: Kur...

– Confirmed objective responses achieved in five of 13 evaluable patients – – Primary endpoint met prior to completion of enrollment with four patients experiencing progression-free survival greater than 6 months – – Proof-of-concept trial sponsored by...

The following slide deck was published by Kura Oncology, Inc. in conjunction with this Read more ...